Article Versions Notes

Machherndl-Spandl S, Hannouf S, Nikoloudis A, Zach O, Strassl I, Kaynak E, Webersinke G, Gruber-Rossipal C, Rumpold H, Schimetta W, et al. Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis. Cancers. 2024; 16(19):3257. https://doi.org/10.3390/cancers16193257

Machherndl-Spandl, Sigrid, Sarah Hannouf, Alexander Nikoloudis, Otto Zach, Irene Strassl, Emine Kaynak, Gerald Webersinke, Christine Gruber-Rossipal, Holger Rumpold, Wolfgang Schimetta, and et al. 2024. "Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis" Cancers 16, no. 19: 3257. https://doi.org/10.3390/cancers16193257

Machherndl-Spandl, S., Hannouf, S., Nikoloudis, A., Zach, O., Strassl, I., Kaynak, E., Webersinke, G., Gruber-Rossipal, C., Rumpold, H., Schimetta, W., Clausen, J., & Buxhofer-Ausch, V. (2024). Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis. Cancers, 16(19), 3257. https://doi.org/10.3390/cancers16193257